Medtronic (MDT) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.62 per share a year ago.
Medtronic said its profit and sales rose during its fiscal fourth quarter, reflecting steps the company has taken to improve business performance and drive growth.
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended April 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the closing of the recent trading day, Medtronic (MDT) stood at $77.6, denoting a -1.27% move from the preceding trading day.
Historically, energy stocks have performed the best when inflation spikes.
Medtronic's Q4 results may get a lift from broad MedSurg growth, strong Cardiovascular demand and continued momentum in Diabetes.
Medtronic eyes a $650 million acquisition of SPR, adding the FDA-cleared SPRINT PNS System to expand its chronic pain treatment offerings ahead of the fiscal 2027 closing.
The latest trading day saw Medtronic (MDT) settling at $77.32, representing a +1.54% change from its previous close.
Surgical robotics is quietly becoming an artificial intelligence story. Every robotic procedure generates structured video, kinematic, and outcomes data that platforms feed back into surgeon training, intraoperative guidance, and predictive analytics.
In the closing of the recent trading day, Medtronic (MDT) stood at $74.54, denoting a -2.11% move from the preceding trading day.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?